Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Merck will showcase results in innovative solutions in HIV treatment and prevention
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Subscribe To Our Newsletter & Stay Updated
